More than Copies: Biosimilars and Pharmaceutical Innovation

In innovation-intensive industries, such as biopharmaceuticals, competition law enforcement must be carefully targeted. If it limits intellectual property rights too strongly, it can weaken the incentives that support pharmaceutical research. If it allows those rights to be used too broadly, it can protect one company in a way that blocks valuable innovation by another. Competition law should protect the rights that make innovation possible, while responding when those rights are abused so as to exclude capable innovators from the research and development race. In this piece, I reflect on my study of innovation competition in the global pharmaceutical industry. Available here: https://lnkd.in/ddR-rFuE